Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
about
Contemporary Treatment of Metastatic Renal Cell CarcinomaSequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinomaWhat links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsPreclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationMedical treatment of renal cancer: new horizonsInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsEfficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudyComparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer CellsDovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsMultitarget inhibitors derived from crosstalk mechanism involving VEGFR2.The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinomaEverolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Sunitinib re-challenge in advanced renal-cell carcinoma.Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialImmunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.Axitinib in sequential therapy in metastatic renal cell carcinoma.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Clinical impact of checkpoint inhibitors as novel cancer therapies.Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Kidney cancer and 2014: is innovation really over?New therapeutic targets for cancer bone metastasisTargeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
P2860
Q26740594-5CFFC1DF-D761-44E5-8CC3-F1DEF5AF0359Q26744089-51760203-4F37-43AE-8E7A-1D99CD2A37C1Q26766240-78F68D31-AFCE-4AEF-8874-B783C824A778Q26772206-D96F41F4-7721-4355-ABE9-6BC54AFBB295Q26773653-E6D24055-F4CD-44D0-A9C8-0ACB4CDF44E4Q26782585-7EB476F7-C6BC-4609-B37C-1D20396D6399Q26801718-98FB1C4D-174E-4BBD-A3B3-1C962555C58AQ27322795-3B5AB2B0-47B0-4347-AFF0-A437B675A0F3Q28073174-88FA8A2C-D072-4AE6-BBB1-A9A9820CC83FQ28079309-6E58981A-8BBA-40BB-80B1-B4E466C76B3BQ28080163-431873DB-FF5E-4602-9D8C-B980D04831E2Q28547506-A97E9BA4-BE0A-478D-95E1-6C33611550C7Q28553202-25CA793E-26D9-41B4-8AC1-D35D2562D135Q33165980-47D421FD-57A3-4A08-9544-376AB7572AFDQ34097937-8E745EF5-5C49-4011-A5CC-6E22456EABFDQ35434188-CB4DCF5C-CD7A-4346-85E5-D7B86A77754BQ35523317-D25EDE3C-B2BB-4A25-A901-361B87FE03C0Q35549876-670103EB-D604-4AE2-9E15-3565B76767C2Q35591889-2E7A5D93-F6D7-4579-9FE3-E75AF75F01A9Q35597799-18D6EA30-73DB-4FD7-A8DD-AF65F1998A26Q35678358-A7409A95-6D91-44FF-BC8B-7894B3D122A9Q35691234-CCAEEEC7-CCFE-4C24-9F35-5A8453B9AEC4Q35752926-65FC28E1-AADD-4FE6-B33D-DE29EF992824Q35892011-DBA81F87-EA79-4417-97D4-98C8B6F7C9A3Q36287386-FF4B7910-599F-49F2-B2CA-B6AC43137CBFQ36726204-31F9C04D-175A-4F0F-84DB-4B66548F7DB6Q37409862-54976BD3-C5A8-4F91-B033-F59F8842EB37Q37727634-31B85475-4813-4776-AD30-1C2BF81924B1Q38201503-9448F7A0-F1D9-4711-AFFA-0C5375A98225Q38262593-17B4DA5B-90E8-4EC7-8D6A-F6263348B7F1Q38264616-9E717E17-98FA-43D2-ABEA-8BB7C28EAC47Q38323440-89128CD4-6E87-4C59-97D9-D7E8CEA52F38Q38382541-2D0E4B56-E6EC-4D4B-9F68-6B6114512345Q38430335-60194BC5-8328-4D65-9B71-96D61AA2ED8BQ38465870-6B3CC520-06B8-4DA5-9087-6E5084A4C39AQ38473066-4AC8DDB8-B51D-43BD-B450-AFE113869B0CQ38473672-99A229D5-70A7-47A5-A4BD-A6669390BBDFQ38485779-A4050F15-BD38-4AC5-854D-139E7F38BC6BQ38497265-E22E0E05-BE6D-43A7-B464-AE37CE318122Q38498207-9A2AFA57-8707-4E12-9EF1-BF3884615558
P2860
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dovitinib versus sorafenib for ...... bel, randomised phase 3 trial.
@en
type
label
Dovitinib versus sorafenib for ...... bel, randomised phase 3 trial.
@en
prefLabel
Dovitinib versus sorafenib for ...... bel, randomised phase 3 trial.
@en
P2093
P2860
P50
P1433
P1476
Dovitinib versus sorafenib for ...... abel, randomised phase 3 trial
@en
P2093
Bernard Escudier
Bohuslav Melichar
Cezary Szczylik
Christian Kollmannsberger
Cora N Sternberg
Gladys Urbanowitz
Ian D Davis
Jae-Lyun Lee
Jakub Zolnierek
P2860
P304
P356
10.1016/S1470-2045(14)70030-0
P577
2014-02-17T00:00:00Z